The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | COVALENT-103: investigating BMF-500, an oral covalent FLT3 inhibitor, in acute leukemias
Marcello Rotta, MD, Colorado Blood Cancer Institute, Denver, CO, introduces the COVALENT-103 trial (NCT05918692), a Phase I, open-label, dose escalation and expansion study that will investigate the safety, tolerability, and efficacy of BMF-500, a novel oral FLT3 inhibitor, in patients with relapsed/refractory (R/R) acute leukemias. This will include acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and mixed-phenotype acute leukemia (MPAL). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
